Efficacy and delivery strategies of the dual Rac/Cdc42 inhibitor MBQ-167 in HER2 overexpressing breast cancer

Trastuzumab and trastuzumab-based treatments are the standard of care for breast cancer patients who overexpress the human epidermal growth factor receptor 2 (HER2). However, patients often develop resistance to trastuzumab via signaling from alternative growth factor receptors that converge to acti...

وصف كامل

التفاصيل البيبلوغرافية

الحاوية / القاعدة:	Translational Oncology
المؤلفون الرئيسيون:	Luis E. Velázquez-Vega, Michael Rivera-Robles, Annelis O. Sánchez-Álvarez, Pablo E. Vivas-Mejía, Miciely Aponte-Reyes, Ailed M. Cruz-Collazo, Nilmary Grafals-Ruiz, Stephanie Dorta-Estremera, Eliud Hernández-O'Farrill, Cornelis P Vlaar, Suranganie Dharmawardhane
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	Elsevier 2024-06-01
الموضوعات:	Rac, Cdc42 MBQ-167 Metastatic breast cancer Trastuzumab HER2-type breast cancer
الوصول للمادة أونلاين:	http://www.sciencedirect.com/science/article/pii/S193652332400055X